| Literature DB >> 30692602 |
Elena Sánchez-López1, Guinevere S M Kammeijer2, Antonio L Crego1, María Luisa Marina1, Rawi Ramautar3, Dorien J M Peters4, Oleg A Mayboroda5.
Abstract
Capillary electrophoresis-mass spectrometry (CE-MS) using a sheathless porous tip interface emerged as an attractive tool in metabolomics thanks to its numerous advantages. One of the main advantages compared to the classical co-axial sheath liquid interface is the increased sensitivity, while maintaining the inherent properties of CE, such as a high separation efficiency and low sample consumption. Specially, the ability to perform nanoliter-based injections from only a few microliters of material in the sample vial makes sheathless CE-MS a well-suited and unique approach for highly sensitive metabolic profiling of limited sample amounts. Therefore, in this work, we demonstrate the utility of sheathless CE-MS for metabolic profiling of biomass-restricted samples, namely for 20 µm-thick tissue sections of kidney from a mouse model of polycystic kidney disease (PKD). The extraction method was designed in such a way to keep a minimum sample-volume in the injection vial, thereby still allowing multiple nanoliter injections for repeatability studies. The developed strategy enabled to differentiate between different stages of PKD and as well changes in a variety of different metabolites could be annotated over experimental groups. These metabolites include carnitine, glutamine, creatine, betaine and creatinine. Overall, this study shows the utility of sheathless CE-MS for biomass-limited metabolomics studies.Entities:
Mesh:
Substances:
Year: 2019 PMID: 30692602 PMCID: PMC6349881 DOI: 10.1038/s41598-018-37512-8
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Comparison of base peak electropherograms of standard metabolite mixture consisting of 60 metabolites at 50 µM (A) and a QC sample of tissue sections (B) obtained with the sheathless CE-MS platform. Experimental conditions: BGE, 10% (v/v) acetic acid (pH 2.3); voltage, +20 kV; sample injection, 1 psi × 60 s (1.4% total volume of the capillary, i.e. roughly 9 nL); 91 cm × 30 µm i.d. × 150 µm o.d. fused-silica capillary.
Figure 2(A) PCA of log-transformed data. (B) PCA of data in (A), excluding QC samples. (C) PCA loading plot of 112 variables in (B), colored according to the modeling power of (B).
Figure 3(A) PLS-DA score plot for the four groups of samples analyzed by the sheathless CE-MS platform. (B) Cross-validated score plot of the PLS-DA plot. (C) VIP vs p(corr) plot, colored according to the VIP values from (B).
Figure 4PLS-DA models for the three different pairwise comparisons performed in this work.
Number of latent variables, quality parameters (R2X, R2Y, Q2 and CV-ANOVA F and p-values) for the pairwise PLS-DA.
| PLS-DA model | Number of latent variables | R2X | R2Y | Q2 | CV-ANOVA | |
|---|---|---|---|---|---|---|
| F | p-value | |||||
| Wt0 | 3 | 0.440 | 0.987 | 0.923 | 35.0 | 3.6 × 10−10 |
| MCK | 3 | 0.569 | 0.988 | 0.967 | 95.0 | 1.4 × 10−14 |
| Wt0 | 2 | 0.311 | 0.969 | 0.857 | 37.8 | 2.9 × 10−14 |
Annotation of variables with VIP values higher than 1.35 (highlighted in bold) in at least a pairwise PLS-DA model from the CE-MS metabolomics analysis of PKD samples.
| Level of assignment | Annotation | Abbreviation | Migration time (min) | Detected specie | Experimental | VIP values of PLS-DA | |||
|---|---|---|---|---|---|---|---|---|---|
| Wt0 | Wt0 vs MCK | MCK | |||||||
| Confirmed with standard | Creatinine | Cre | 13.4 | [M+H]+ | 114.0671 115.0697 | 0.9 mDa |
| 1.30 | |
| Carnitine | Carn | 15.4 | [M+H]+ | 163.1159 (isotopic profile of 162.1139) 164.1173 | 1.4 mDa | 0.37 0.31 | 0.91 0.95 |
| |
| Creatine | Cr | 17.0 | [M+H]+ | 133.0796 (isotopic profile of 132.0782) | 1.4 mDa |
|
| 0.20 | |
| Glutamine | Gln | 21.0 | [M-NH3+H]+ | 130.0503 | 0.5 mDa | 1.27 |
| 0.59 | |
| Betaine | Btn | 22.9 | [M+H]+ | 119.0899 (isotopic profile of 118.0884) | 2.1 mDa | 0.12 | 0.44 |
| |
| Tentative annotation | 1-methylhistidine | mHis | 14.6 | [M+H]+ | 170.0925 171.0955 | 0.1 mDa |
|
| 0.25 0.26 |
| Acetylcholine | Ach | 14.7 | [M+H]+ | 146.1178 | 0.2 mDa | 0.91 |
| 0.72 | |
| 4-Guanidinobutanoic acid | Gba | 15.0 | [M+H]+ | 146.0927 | 0.3 mDa | 1.04 |
|
| |
| 2-Aminooctanoic acid | AoA | 15.2 | [M+H]+ | 160.1334 161.1367 | 0.2 mDa |
|
| 0.94 0.96 | |
| Methylguanine (different isomers are possible) | mGu | 15.2 | [M+H]+ | 166.0725 | 0.2 mDa | 0.46 | 0.61 |
| |
| γ-L-Glutamylputrescine or N5-(1-imino-3-butenyl)-L-ornithine | Gput | 15.4 | [M-H2O+H]+ | 200.1393 | 0.6 mDa |
|
| 1.01 | |
| Formylisoglutamine | fGln | 15.4 | [M+H]+ | 175.0715 | 0.2 mDa | 0.14 | 1.04 |
| |
| Imidazolelactic acid | ILA | 16.3 | [M+H]+ | 157.0609 | 0.1 mDa |
|
| 0.73 | |
| Asn-Hydroxyproline or Hydroxyprolyl-Asn | P1 | 16.5 | [M+H]+ | 246.1083 | 0.1 mDa |
| 1.29 |
| |
| Argininic acid | ArgA | 16.5 | [M+H]+ | 176.1030 | 0.0 mDa | 0.20 | 0.19 |
| |
| Propionyl-L-carnitine | Pcarn | 16.6 | [M+H]+ | 218.1386 219.1417 | 0.1 mDa |
| 0.92 0.90 | 1.28 1.27 | |
| Homocitrulline | Hcit | 16.8 | [M+H]+ | 190.1185 | 0.1 mDa | 1.09 | 0.30 |
| |
| Glycyl-lysine or lysyl-glycine | P2 | 17.4 | [M+H]+ | 204.1342 | 0.1 mDa | 0.68 | 0.28 |
| |
| N-α-Acetyl-L-arginine | Aarg | 17.7 | [M+H]+ | 217.1286 | 0.9 mDa |
| 0.82 |
| |
| 3-Hydroxyisovalerylcarnitine | HIVC | 17.7 | [M+H]+ | 262.1647 | 0.2 mDa |
| 0.43 |
| |
| (1) Phe-Thr or Thr-Phe (2) Hydroxyproline-Leu(Ile), or Leu(Ile)-Hydroxyproline | P3 | 18.5 | [M+H]+ (1) [M+Na]+ (2) | 267.1339 268.1370 | 0.9 mDa |
| 1.57 1.86 |
| |
| 2-[3-carboxy-3-(methylammonio)propyl]-L-histidine | CMHis | 19.0 | [M+H]+ | 271.1400 | 0.1 mDa | 0.52 | 1.27 |
| |
| Proline betaine | ProB | 23.1 | [M+H]+ | 144.1023 | 0.4 mDa |
|
|
| |
| γ-carboxyglutamic acid | Gla | 32.1 | [M+H]+ | 192.0501 | 0.2 mDa | 1.26 | 0.83 |
| |
| 5-Hydroxyindoleacetylglycine | hINaG | 32.1 | [M-H2O+H]+ | 231.0764 | 0.6 mDa |
|
|
| |
| Pantothenic acid | PA | 32.2 | [M-H2O+H]+ | 202.1074 | 0.5 mDa | 0.06 | 0.15 |
| |
Figure 5Correlational relationships between the annotated metabolites within each of the four experimental groups. For abbreviations see Table 2.